Sign up to save your podcasts
Or
Share Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study.
Join us as we delve into:
• The significance of MSI-high status in colorectal cancer and its prevalence.
• The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates.
• The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy.
• Important side effects associated with the combination therapy and how to manage them.
• Insights on patient selection for immunotherapy, including considerations for age and comorbidities.
• The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment.
YouTube: https://youtu.be/wJRlECiY2VA
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025!
#OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW
View all episodes
By Oncology Brothers
4.8
4040 ratings
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study.
Join us as we delve into:
• The significance of MSI-high status in colorectal cancer and its prevalence.
• The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates.
• The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy.
• Important side effects associated with the combination therapy and how to manage them.
• Insights on patient selection for immunotherapy, including considerations for age and comorbidities.
• The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment.
YouTube: https://youtu.be/wJRlECiY2VA
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025!
#OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
323 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
121 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
294 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,361 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
205 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
192 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners